Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

• Status: Recruiting
• Trial end date: 2023-11-01

Summary

Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with PSA progression on abiraterone.

• Phase: Phase 1

Details

• Lead Sponsor: Arvinas Androgen Receptor, Inc.